Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia

Netherlands Journal of Medicine

Volumn 53, Issue 5, 1998, Pages 228-233

  Stuyt, P M J ^a   Kleinjans, H A J ^b   Stalenhoef, A F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Acipimox; Familial hypercholesterolemia; Lipid lowering therapy; Lipoproteins; Simvastatin

Indexed keywords

ACIPIMOX; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FLUSHING; HUMAN; MALE; SIDE EFFECT; STOMACH DISEASE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, VLDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRAZINES; SAFETY; SIMVASTATIN;

EID: 0031769691     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(98)00076-X     Document Type: Article

References (22)

1. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Stanbury JB, Wijngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, editors. The metabolic basis of inherited disease. New York: McGraw-Hill Book Company, 1983:672-712.
2. Mol MJTM, Erkelens DW, Gevers Leuven JA, Schouten JA, Stalenhoef AFH Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia. Lancet. 2:1986;936-939.
3. Mol MJTM, Erkelens DW, Gevers Leuven JA, Schouten JA, Stalenhoef AFH Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolemia. Atherosclerosis. 69:1988;131-137.
4. Grundy SM HMG CoA reductase inhibitors for the treatment of hypercholesterolemia. N Engl J Med. 319:1988;23-33.
5. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
6. Kane JP, Malloy MJ, Tun Pet al. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med. 304:1981;251-258.
7. Fucella LM, Golarriga G, Lovisolo PPet al. Inhibition of lipolysis in man by nicotinic acid and by acipimox, a new anti-lipolytic agent. Clin Pharmacol Ther. 28:1980;790-795.
8. Crepaldi G, Avogaro P, Descovich GCet al. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial. Atherosclerosis. 70:1988;115-121.
9. Stuyt PMJ, Stalenhoef AFH, Demacker PNM, van 't Laar A A comparative study of the effects of acipimox and clofibrate in type III and IV hyperlipoproteinemia. Atherosclerosis. 55:1985;51-62.
10. Carlson LA, Hamsten A, Asplund A Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Int Med. 226:1989;271-276.
11. Seed M, O'Connor B, Perombledon N, O'Donnell M, Reavely D, Knight BL The effect of nicotinic acid and acipimox on lipoprotein (a) concentration and turnover. Atherosclerosis. 10:1993;61-68.
12. Hoogerbrugge N, Jansen H, de Heide L, Zillikens MC, Deckers JW, Birkenhäger JC The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. J Int Med. 241:1997;151-155.
13. Garg R, Malinow R, Petinger M, Hunninghake H Treatment with niacin increases plasma homocyst(e)ine levels (abstract). Circulation. 94:1996;I-457.
14. Demacker PNM, Boerma GJM, Baadenhuijsen H, van Strik J, Jansen AP Evaluation of accuracy of 20 different test kits for the enzymatic determination of cholesterol. Clin Chem. 29:1983;1916-1922.
15. Demacker PNM, Hijmans AG, Vos-Janssen HE, van 't Laar A A study of the use of polyethylene glycol in estimating cholesterol in high density lipoprotein. Clin Chem. 26:1980;1775-1779.
16. Demacker PNM, Hijmans AG, Brenninkmeijer BJ, Jansen AP, van 't Laar A Five methods for determing low density lipoprotein cholesterol compared. Clin Chem. 30:1984;1797-1800.
17. Lopez-Virella MF, Virella G, Evans G, Malenkos SB, Colwell JA Immunonephelometric assay of human apolipoprotein A1. Clin Chem. 26:1980;1205-1208.
18. Esterbauer H, Striegl G, Puhl H, Rotheneder M Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 6:1989;67-75.
19. de Rijke YB, Bredie SJH, Demacker PNM, Vogelaar JM, Hak-Lemmers HLM, Stalenhoef AFH The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification; studies on subjects with familial combined hyperlipidemia. Arteriosc Thromb. 17:1997;127-133.
20. Boers GHJ, Smals AGH, Trijbels JMF, Leermakers AI, Kloppenborg PWC Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest. 72:1976;1971-1976.
21. de Graaf J, Hendriks J, Demacker PNM, Stalenhoef AFH Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. Arterioscler Thromb. 13:1993;712-719.
22. Bredie SJH, de Bruin TWA, Demacker PNM, Kastelein JJP, Stalenhoef AFH Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile and low-density lipoprotein oxidizability. Am J Cardiology. 75:1995;348-353.